What’s new

• EBITDA margin guidance dropped to 23-25% from 25-27%.
• 500-bed capacity target deferred by one year to 2028.
• Bone marrow transplant unit delayed 4-5 months pending state policy approval.

Why it matters

The combination of margin compression and deferred capacity expansion suggests execution headwinds that management has yet to fully clarify. While revenue growth targets remain ambitious at 50%, the lack of transparency regarding the one-year delay in the 500-bed roadmap is a red flag for investors.

What we’re watching

• Closure of the nearly settled hospital acquisition.
• State government policy approval for the bone marrow transplant unit.
• Actual revenue performance against the ₹250-260 crore FY27 target.

The full read

Asarfi Hospital is recalibrating its growth path. During its May 27, 2026, conference call, management lowered its medium-term EBITDA margin target to 23-25% from the previous 25-27% range. The company also pushed its 500-bed capacity goal back by one year to 2028 without providing a clear explanation for the delay. While the company is targeting ₹250-260 crore in revenue for FY27—a 50% jump from the ₹173.5 crore recorded in FY26—that projection relies partly on an acquisition that is nearly settled but not yet closed. Operational progress continues in pockets, with cancer hospital revenue up 65% to ₹33 crore and new equipment like the Philips Azurion Cath lab coming online. However, the bone marrow transplant unit remains stalled for 4-5 months pending state policy approvals. The open question is whether the inorganic growth can offset the margin compression and the slower pace of capacity expansion.

Primary source: BSE · NSE